Medical Condition News

RSS

Vexim receives CE Mark approval for 6.5 mm diameter SpineJack implant

Vexim, the specialist in minimally invasive anatomical restoration of vertebral compression fractures, today announced the CE Marking and the market launch of its 6.5 mm diameter SpineJack implant, which thus guarantees the technology's compliance and safety.

29 Aug 2011

Pfizer's Xalkori receives FDA approval to treat late-stage NSCLC patients with abnormal ALK gene

The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers (NSCLC) who express the abnormal anaplastic lymphoma kinase (ALK) gene.

29 Aug 2011

Individuals with BAP1 gene mutation more likely to develop mesothelioma

Scientists have found that individuals who carry a mutation in a gene called BAP1 are susceptible to developing two forms of cancer - mesothelioma, and melanoma of the eye.

29 Aug 2011

ELIQUIS better than warfarin in reduction of stroke, major bleeding, and mortality

Bristol-Myers Squibb Company and Pfizer Inc. today announced the main results of the Phase 3 clinical trial ARISTOTLE, which evaluated ELIQUIS compared to warfarin for the prevention of stroke or systemic embolism in 18,201 patients with atrial fibrillation and at least one risk factor for stroke.

29 Aug 2011

AAO-HNSF's 2011 Annual Meeting & OTO EXPO to convene in San Francisco

The 2011 Annual Meeting & OTO EXPO of the American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF), the largest meeting of ear, nose, and throat doctors in the world, will convene September 11-14, 2011, in San Francisco, CA.

29 Aug 2011

MitraClip treatment could benefit heart failure patients who are unresponsive to CRT

Results of an observational study presented at the European Society of Cardiology (ESC) meeting today in Paris demonstrate that the percutaneous catheter-based MitraClip treatment improves symptoms and promotes reverse left ventricular (LV) remodeling in patients with mitral regurgitation (MR), who do not respond to cardiac resynchronization therapy.

29 Aug 2011

New clinical data shows positive long-term performance of Medtronic's CoreValve system

New clinical data presented today at the European Society of Cardiology Congress 2011 demonstrate positive long-term performance for the CoreValve transcatheter aortic valve replacement system from Medtronic, Inc.

From Medtronic 29 Aug 2011

Low-cost device to help physicians detect and diagnose cancer

An engineering researcher and a global health expert from Michigan State University are working on bringing a low-cost, hand-held device to nations with limited resources to help physicians detect and diagnose cancer.

29 Aug 2011

U.S. medical costs linked with treatment of preventable diseases to reach $66B per year

The rising prevalence of obesity around the globe places an increasing burden on the health of populations, on healthcare systems and on overall economies. A major challenge for researchers is to quantify the effect of these burdens to inform public policies.

29 Aug 2011

Colchicine more effective than placebo for recurrent pericarditis

Colchicine, when given in addition to conventional therapy, was more effective than placebo in reducing the incidence of recurrence and the persistence of symptoms of pericarditis in a randomised controlled trial.

29 Aug 2011

Scientists identify six new genetic variants associated with type 2 diabetes in South Asians

An international team of researchers led by Imperial College London has identified six new genetic variants associated with type-2 diabetes in South Asians. The findings, published in Nature Genetics, give scientists new leads in the search for diagnostic markers and drug targets to prevent and treat this major disease.

29 Aug 2011

LUNGevity Foundation applauds FDA's recent approval of XALKORI lung cancer drug

LUNGevity Foundation applauds the US Food and Drug Administration's (FDA) recent approval of XALKORI (crizotinib) to treat lung cancer. The drug, introduced by Pfizer, Inc. showed such promise in early trials that it was given "fast track" status by the FDA.

29 Aug 2011

Astellas seeks regulatory approval for mirabegron to treat overactive bladder in the U.S., Europe

Astellas Pharma Inc. today announced the submission of a New Drug Application and Market Authorisation Application for mirabegron to the U.S. Food and Drug Administration and the European Medicines Agency.

29 Aug 2011

Apixaban superior to warfarin in preventing stroke and systemic embolism

A large-scale trial finds that apixaban, a new anticoagulant drug, is superior to the standard drug warfarin for preventing stroke and systemic embolism in patients with atrial fibrillation.

29 Aug 2011

New research: Inattention associated with educational failure

New research from the University of Montreal shows that inattention, rather than hyperactivity, is the most important indicator when it comes to finishing a high school education.

29 Aug 2011

Researchers identify molecule that can stop the formation of amyloid fibrils

A molecule which can stop the formation of long protein strands, known as amyloid fibrils, that cause joint pain in kidney dialysis patients has been identified by researchers at the University of Leeds.

29 Aug 2011

FDA approves Abbott's Vysis ALK FISH test for NSCLC therapy selection

Abbott today announced it has received approval from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic test designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer.

29 Aug 2011

'Electronic nose' smells heart failure

A German team has developed a completely new non-invasive method to identify heart failure. It consists of an "electronic nose" which could make the "smelling" of heart failure possible. The projet was presented at the ESC Congress 2011 today.

29 Aug 2011

Pfizer receives FDA approval for XALKORI capsules to treat ALK-positive NSCLC

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XALKORI (crizotinib) capsules, the first-ever therapy targeting anaplastic lymphoma kinase (ALK), for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by an FDA-approved test.

29 Aug 2011

Azithromycin can help reduce wheezing, other acute symptoms of COPD

A common antibiotic can help reduce the severe wheezing and other acute symptoms of chronic obstructive pulmonary disease, according to a large, multicenter clinical trial sponsored by the National Institutes of Health and conducted at the University of California, San Francisco (UCSF).

29 Aug 2011